You are here

Structural Heart

 - Patient

French researchers suggest that with the right transcatheter aortic valve, the right approach, local anesthesia and minimal complications, patients can be discharged early with no added risk. 

 - ecg, heart, electrophysiology

In an international, real-world setting, two-thirds of late transcatheter aortic valve replacement (TAVR) cardiac deaths could be traced back to advanced heart failure and sudden cardiac death. Researchers found, however, some factors that led to increased risks in these patients were modifiable. 

 - electrophysiology, ICD, pacemaker

Pacemaker implantation after transcatheter aortic valve replacement (TAVR) may increase repeat hospitalization and mortality risks at 30 days and one year, according to a study published in the January issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.

 - Brigham & Women's Hospital

Michael J. Davidson, MD, director of endovascular cardiac surgery at Brigham and Women’s Hospital in Boston, died late Tuesday after being shot twice at the hospital’s heart center.

 - heart valves

A study comparing three transcatheter aortic valve replacement (TAVR) devices found them similarly effective at 30 days. 


More Stories

Technology & the future of pediatric cardiology

Miniaturization and 3D modeling help to provide new technologies to meet the needs of pediatric patients with congenital heart defects.

Results in mid-risk patients give next-gen TAVR valve a boost

Transcatheter aortic valve replacement (TAVR) likely stepped closer to use in intermediate-risk patients after a multicenter study found patients who underwent transfemoral TAVR with a next-generation valve had a 30-day mortality rate of 2.1 percent.

ARB offers no benefit over beta-blockers for Marfan’s patients

For patients with Marfan’s syndrome, losartan may not be any better at reducing rates of aortic-root enlargement than beta-blockers. The results challenge prior studies that suggested losartan may have an advantage over beta-blocker therapy.

Cardio3 snaps up valve access business

The Belgian biotechnology company Cardio3 BioSciences acquired a device maker that specializes in heart access technologies for an undisclosed amount.

Mitroflow analysis finds early, frequent valve deterioration

French cardiac surgeons raised a red flag about the 12A/LX models of the Mitroflow valve, warning of a potential epidemic of structural valve deterioration and valve-related deaths in patients implanted with the devices.

Genetically high LDL-C may increase risk for aortic valve disease

According to a multinational study, genetically high levels of low-density lipoprotein cholesterol (LDL-C) may put patients at increased risk for aortic valve disease. No similar association was found between high-density lipoprotein cholesterol (HDL-C) or triglycerides and the development of aortic valve calcium and stenosis.

First mitral procedures show transapical implantation is feasible

Transcatheter mitral valve implantation looks like the next frontier in treatments for patients who are at high risk for surgical valve repair or replacement. In a first-in-man report, physicians demonstrated that a transapical approach is technically feasible and potentially safe.

Congenital heart program nips radiation dose by 61 percent

Initiating a radiation safety protocol in their congenital heart center reduced the cumulative radiation dose in patients undergoing catheterizations by 61 percent, cardiologists reported in the November issue of Catheterization and Cardiovascular Interventions.

Hospitals readmit 1 in 5 patients after cardiac operations

Almost one in five patients who undergo cardiac surgery get readmitted, with the vast majority rehospitalized within 30 days. The findings, published in the October issue of the Annals of Thoracic Surgery, have implications for future quality measures.

Aortic valve replacement study reconsiders guidelines, younger patients

Mechanical and bioprosthetic aortic valve replacements were found to be equally safe and effective for patients aged 50 to 59 years, according to a study published Oct. 1 in JAMA. No difference was seen in stroke or long-term survival rates between the two replacement options.

Repositionable Lotus valve safe, effective at 30 days

A repositionable and retrievable valve proved safe and effective at 30 days in high-risk patients who underwent transcatheter aortic valve replacement. Results from the REPRISE II study were published in the Sept. 30 issue of the Journal of the American College of Cardiology.

St. Jude puts Portico on hold

St. Jude Medical has hit the pause button on its Portico resheathable heart valve used in transcatheter aortic valve replacement (TAVR) procedures after reports of reduced leaflet mobility.

Growing up on statins: Checking up on kids 10 years out

Children with familial hypercholesterolemia who were given statins as treatment slowed the progression of their mean carotid intima media thickness after 10 years of treatment to nearly normal rates, according to research published Sept. 10 in JAMA.

Money & MitraClip

It appears that the Centers for Medicare & Medicaid Services (CMS) may compromise on reimbursement for MitraClip implantations. If so, you probably have your colleagues and societies to thank for it.

Meta-analysis finds 2.5-fold higher pacemaker risk with CoreValve

A meta-analysis of predictors of permanent pacemaker implantation after transcatheter aortic valve replacement (TAVR) reinforced findings that patients treated with the CoreValve device were at increased risk compared with patients receiving the Sapien device. The predictors may help physicians avoid atrioventricular block-related complications, regardless of device type.

Device size, failure mode affect outcomes after valve-in-valve procedure

Patients with baseline stenosis or small surgical valves who undergo transcatheter aortic valve-in-valve implantation for failed bioprosthetic devices have lower survival rates than the overall patient population, according to a study published in the July 9 issue of JAMA.

Women bore brunt of initial NCD for TAVR

Limiting access to transcatheter aortic valve replacement (TAVR) therapy to inoperable patients suitable for only a transfemoral approach reduced the number of patients who received care, particularly women, in a study that evaluated the effect of the national coverage determination (NCD). 

Surgeons warn against use of Mitroflow valve in young patients

Children’s hospital physicians cautioned surgeons against implanting the Mitroflow bioprosthetic aortic valve in young patients who undergo aortic valve replacement and recommended vigilant surveillance of those who already have the device.

Congenital heart disease longevity increasing in Quebec

People with congenital heart disease are living longer and both birth and longevity rates in Quebec and the rest of Canada are comparable to statistics from other industrialized nations. Over time, this is leading to growth of an aging congenital heart disease population, particularly for those with severe disease with comorbid conditions, according to a study published online June 18 in Circulation.

Antidepressants not likely to increase risk of cardiac birth defects

The risk of children developing heart defects due to maternal antidepressant use in the first trimester may be lower than originally thought, according to a study published June 18 in the New England Journal of Medicine. These findings challenge the FDA’s decision to classify selective serotonin-reuptake inhibitors as Category D medications (evidence of human fetal risk, but benefits may warrant use) in pregnancy.